Logo image of GUTS

FRACTYL HEALTH INC (GUTS) Stock Fundamental Analysis

NASDAQ:GUTS - Nasdaq - US35168W1036 - Common Stock - Currency: USD

1.52  0 (0%)

After market: 1.51 -0.01 (-0.66%)

Fundamental Rating

2

Taking everything into account, GUTS scores 2 out of 10 in our fundamental rating. GUTS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. GUTS may be in some trouble as it scores bad on both profitability and health. GUTS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GUTS had negative earnings in the past year.
GUTS had a negative operating cash flow in the past year.
GUTS had negative earnings in each of the past 5 years.
GUTS had a negative operating cash flow in each of the past 5 years.
GUTS Yearly Net Income VS EBIT VS OCF VS FCFGUTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -107.31%, GUTS is doing worse than 82.35% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1397.65%, GUTS is doing worse than 90.91% of the companies in the same industry.
Industry RankSector Rank
ROA -107.31%
ROE -1397.65%
ROIC N/A
ROA(3y)-97.75%
ROA(5y)-92.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GUTS Yearly ROA, ROE, ROICGUTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

The Gross Margin of GUTS (48.33%) is comparable to the rest of the industry.
GUTS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GUTS Yearly Profit, Operating, Gross MarginsGUTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

GUTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GUTS has been increased compared to 1 year ago.
GUTS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for GUTS has been reduced compared to a year ago.
GUTS Yearly Shares OutstandingGUTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
GUTS Yearly Total Debt VS Total AssetsGUTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -10.26, we must say that GUTS is in the distress zone and has some risk of bankruptcy.
GUTS has a Altman-Z score of -10.26. This is amonst the worse of the industry: GUTS underperforms 81.28% of its industry peers.
A Debt/Equity ratio of 4.61 is on the high side and indicates that GUTS has dependencies on debt financing.
The Debt to Equity ratio of GUTS (4.61) is worse than 90.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.61
Debt/FCF N/A
Altman-Z -10.26
ROIC/WACCN/A
WACC7.88%
GUTS Yearly LT Debt VS Equity VS FCFGUTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 2.50 indicates that GUTS has no problem at all paying its short term obligations.
The Current ratio of GUTS (2.50) is comparable to the rest of the industry.
GUTS has a Quick Ratio of 2.50. This indicates that GUTS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GUTS (2.50) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.5
Quick Ratio 2.5
GUTS Yearly Current Assets VS Current LiabilitesGUTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.06% over the past year.
GUTS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -60.78%.
EPS 1Y (TTM)11.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.24%
Revenue 1Y (TTM)-60.78%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, GUTS will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.63% on average per year.
Based on estimates for the next years, GUTS will show a very strong growth in Revenue. The Revenue will grow by 358.31% on average per year.
EPS Next Y-2%
EPS Next 2Y-7.81%
EPS Next 3Y4.67%
EPS Next 5Y11.63%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y405.28%
Revenue Next 5Y358.31%

3.3 Evolution

GUTS Yearly Revenue VS EstimatesGUTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 50M 100M 150M 200M
GUTS Yearly EPS VS EstimatesGUTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GUTS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GUTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GUTS Price Earnings VS Forward Price EarningsGUTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GUTS Per share dataGUTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.81%
EPS Next 3Y4.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GUTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FRACTYL HEALTH INC

NASDAQ:GUTS (7/11/2025, 8:19:51 PM)

After market: 1.51 -0.01 (-0.66%)

1.52

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners81.32%
Inst Owner Change0%
Ins Owners4.26%
Ins Owner Change0.71%
Market Cap74.45M
Analysts84.44
Price Target9.52 (526.32%)
Short Float %5.35%
Short Ratio4.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.99%
Min EPS beat(2)-17.2%
Max EPS beat(2)-0.78%
EPS beat(4)2
Avg EPS beat(4)2.79%
Min EPS beat(4)-17.2%
Max EPS beat(4)23.27%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.86%
EPS NY rev (1m)-6%
EPS NY rev (3m)-7.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1240.83
P/FCF N/A
P/OCF N/A
P/B 11.68
P/tB 11.68
EV/EBITDA N/A
EPS(TTM)-1.85
EYN/A
EPS(NY)-1.78
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS0
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -107.31%
ROE -1397.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.33%
FCFM N/A
ROA(3y)-97.75%
ROA(5y)-92.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 4.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 126.26%
Cap/Sales 1923.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.5
Quick Ratio 2.5
Altman-Z -10.26
F-Score2
WACC7.88%
ROIC/WACCN/A
Cap/Depr(3y)132.87%
Cap/Depr(5y)81.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-188.24%
EPS Next Y-2%
EPS Next 2Y-7.81%
EPS Next 3Y4.67%
EPS Next 5Y11.63%
Revenue 1Y (TTM)-60.78%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y405.28%
Revenue Next 5Y358.31%
EBIT growth 1Y-33.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.23%
EBIT Next 3Y-11.11%
EBIT Next 5YN/A
FCF growth 1Y-55.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53%
OCF growth 3YN/A
OCF growth 5YN/A